Extensive real-world evidence demonstrates that biosimilar anti-TNF-α medicines can offer substantial benefits to both patients with IBD and healthcare systems, and the change in regional and international guidelines reflects a broader paradigm shift to maximize benefits via ‘top-down’ treatment approaches, particularly for moderate-to-severe disease. This evidence concerns the gene TNF and inflammatory bowel disease.